TipRanks
Were a little over one week past the Presidential election, and the market reaction shows that that investors are pleased. While the election margins were razor thin, the will of the voters came through: they rejected Donald Trump, and his brash, in-your-face style, but they also rejected the Democratic Party on policy; the Dems lost seats in the House, will likely not take control of the Senate, and also lost ground at the State level. Americas voters seem to be tired of drama, whether it comes from Donald Trump or the Democrats push to the political left. They want a government that will simply plod straight along.And it looks like they will get just that. With power split in the White House and the Chambers of Congress, were about to be reminded of a feature of the checks and balance system: that gridlock is a result of a closely divided electorate. Change wont happen unless one side or the other gets a large majority, or a small majority over several terms. Neither of those is in the cards for now.The immediate result is a multi-day market rally. The implication is clear the markets sentiment has calmed since the election, and investors look forward to government settling into a more normal mode in the coming months.To this end, investors are sure to find solid options in the near term. Writing from Raymond James, analyst Ric Prentiss has recently published three reviews on mid-cap stocks, pointing out why, in his view, they offer high return potential with more settled markets in the coming year. The stocks all fit a profile: they are at the lower end of the mid-cap range, with market valuations between $2 billion and $3 billion; they inhabit the telecom ecosystem, and they all have, according to Raymond James, over 80% upside potential. We ran the the three through TipRanks database to see what other Wall Street's analysts have to say about them.Telephone & Data Systems (TDS)First on our list, Telephone & Data Systems, is a Chicago-based company providing a range of telecom services to over 6 million customers. The company offers broadband over cable and wireline, wireless products and services, and TV and voice services. TDS operates the countrys fifth-largest cellular carrier.TDS has dramatically outperformed expectations in 2020, despite the ongoing coronavirus. Revenues, at $1.32 billion, are about level with the pre-corona report ($1.34 billion in Q4 2019), while earnings jumped in 1Q20 and have remained high ever since. The Q3 earnings, at 66 cents, beat the forecast by 153%. It was an impressive performance, made more so by the 266% year-over-year growth.On another bright note for investors, TDS has maintained its dividend payment through the year. The 17-cent per common share payout annualizes to 68 cents, and offers a yield of 3.6%, nearly double the average yield found among S&P-listed companies.TDS has shown strong business through the year, but its weak point has been in the fiber and wireline niche. However, Raymond James Ric Prentiss looks at the half-full glass, noting: "WFH policies have continued to result in some slower approvals from municipalities and electrical utilities associated with building aerial fiber. And in some cases, TDS is pivoting to alternatives with better economics. Still, TDS Telecom grew fiber service addresses 5% y/y and is seeing better-than-expected take rates around 30-40%, depending on the market. Moreover, 34% of Wireline customers are now served by fiber, compared to 29% a year ago, and TDS expects acceleration throughout the rest of 2020."Prentiss rates TDS as a Strong Buy, and increased his price target by 6% to $34. At that level, he sees an 81% upside for the stock over the next months. (To watch Prentisss track record, click here)This stock also holds a Strong Buy rating from the analyst consensus, based on 3 unanimous Buy reviews set in recent weeks. Shares are priced at $18.73 and the average target of $34.83 suggests a one-year upside of 85.5%. (See TDS stock analysis on TipRanks)ViaSat, Inc. (VSAT)Next up, ViaSat, is a high-speed satellite broadband provider. The California company serves commercial and defense markets, building on the broad need, across industries, for secure communications.Social lockdown measures took a toll on the companys business, especially the shutdowns of airlines. Commercial air traffic relies heavily on satellite communications, and that slowdown is still weighing on ViaSat.The headwinds are partially offset by a backlog in services ordered. Revenues have remained stable over the past four quarters, between $530 million and $588 million, with the $554 million recorded in Q3 being solidly in the middle of that range. Earnings have bounced back into positive territory after turning negative in Q2. The third quarter EPS was only 3 cents, but that was a dramatic sequential improvement from the previous 20-cent net loss.In his look at VSAT, Prentiss notes, Government Systems and Commercial Networks remain strong, while the IFC business continues to navigate significant headwinds related to COVID-19 On the positive side, social distancing and Safer-At-Home policies are driving more residential broadband data usage and pushing ARPUs higherPrentiss rates VSAT an Outperform (i.e. Buy) while his $63 price target suggests an 87% upside potential.Overall, ViaSat gets a Moderate Buy rating from the analyst consensus, based on 3 reviews that include 2 Buys and 1 Hold. The shares have an average price target of $53.33, which implies a 12-month upside of 59% from the trading price of $33.39. (See VSAT stock analysis on TipRanks)EchoStar Corporation (SATS)Last but not least is EchoStar, another satellite operator. This company controls a constellation of communications satellites, offering satcom capabilities to the media and private enterprises, as well as both civilian and military US government agencies. In addition, EchoStar provides satellite broadband in 100 countries around the world.At the top line, EchoStar's revenues have held steady for the past three quarters, coming in at $465 million, $459 million, and $473 million. And while earnings were negative in Q1 and Q2, the Q3 results showed a net profit of 26 cents per share.The sequential Q3 improvements at the top and bottom lines come along with increases in the EchoStars subscriber base, to more than 1.54 million in total. The company also boasts a strong balance sheet, having more than $2.5 billion in cash on hand and no net debt.Covering SATS, Ric Prentiss is upbeat about near- and mid-term prospects. He writes, SATS [has] strategic optionality in a time when others, especially higher levered satellite companies, are cash starved facing significant maturities or capex programs we think a number of organic and inorganic growth options are being considered, including the future deployment of SBand spectrum after lining up anchor tenant(s). Lastly, we believe EchoStar's recently announced collaboration with Inmarsat to provide capacity for In-Flight Connectivity should provide over time high margin cash flows, and we note the deal is not exclusive.These comments back another Strong Buy rating, and Prentisss $57 target price indicates room for 123% growth in the next year. In terms of other analyst activity, it has been relatively quiet. 1 Buy and 1 Hold ratings assigned in the last three months add up to a Moderate Buy analyst consensus. In addition, the $43.50 average price target puts the upside potential at ~74%. (See SATS stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
- Research shows need for better mpox protection in HIV-positive patients - The Pharma Letter - April 5th, 2025
- Marine Biotechnology Market to Reach $10.37 Bn by 2032 with 6.2% CAGR - openPR.com - April 5th, 2025
- Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana... - April 5th, 2025
- Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class... - April 5th, 2025
- Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future - Analytics Insight - February 24th, 2025
- The Security Implications of Developments in Biotechnology - International Institute for Strategic Studies - February 24th, 2025
- Biotechnology Permits and Notifications - USDA APHIS - February 24th, 2025
- Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage - Nature.com - February 24th, 2025
- Internal cap-initiated translation for efficient protein production from circular mRNA - Nature.com - February 24th, 2025
- MIT class takes students on a grand tour of the interdisciplinary world of biotech - MIT News - February 24th, 2025
- BioTech Breakthrough Awards BostonGene With Cancer Immunology Solution of the Year - Business Wire - February 24th, 2025
- Biodiversity to Bioeconomy - PIB - February 24th, 2025
- Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment... - February 24th, 2025
- Biofach 2025: Biosan Biotechnology CEO talks popular mushroom blends and wellness benefits - Nutrition Insight - February 24th, 2025
- Pushing the boundaries of biotechnology - UC Santa Cruz - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims & More: Daily Recap (1/26/25) - WDW News Today - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims in EPCOT - WDW News Today - January 27th, 2025
- Biotechnology led to dramatic innovations in agriculture and human health in 2024 - Genetic Literacy Project - January 27th, 2025
- Cultured algae and biotechnology are ingredients to the 'Gelato of the future' - STIRworld - January 27th, 2025
- New U.S. Export Controls Seek to Prevent China From Weaponizing Biotech - Foundation for Defense of Democracies - January 27th, 2025
- Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? - Nature.com - January 27th, 2025
- Nuevocor Welcomes Andreas Wallnfer as Chairman of the Board of Directors - Kilgore News Herald - January 27th, 2025
- Creating and sustaining university biotech spin-outs - PMLiVE - January 27th, 2025
- IMTECH celebrates 41st foundation day with focus on BioE3 policy and biotechnology innovations - The Times of India - January 27th, 2025
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024